We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
The Swiss pharma group needs to settle investor jitters with its latest acquisition
Swiss pharmaceutical group is under pressure to strengthen its pipeline of medicines
Bolt-on acquisitions, however interesting, will not get Swiss pharmaceuticals group Roche out of its funk
Swiss pharma group acquires rights to develop and manufacture bowel disease treatment
Shares in Swiss pharma group rally after analyst discovers data on immunotherapy medicine on website
BNP Paribas joins environmentalists in pressing companies to run toxin tests with synthetic substances
Two studies of antibody treatment gantenerumab fail to slow decline in people with early-stage disease
Swiss pharma group says demand for coronavirus tests dropped as severity of virus ebbed
Severin Schwan will be succeeded by Thomas Schinecker, head of drugmaker’s diagnostics unit
Do not dismiss the possibility of another upturn in the coronavirus testing market
Swiss pharmaceuticals group expects revenue from coronavirus treatments will decline this year
New therapies replace a blunderbuss with a stiletto
Twenty-year shareholding had kept the two Swiss drugmakers closely linked
Plus, inside the cut-throat game of private equity and European football
The Swiss company and Japanese tech investor both have a taste for big data and disruption
Deal struck through unit of Japanese technology group that was behind ‘Nasdaq whale’ trade
Hypothesis that brain plaques cause disease viewed with scepticism by some scientists
Severin Schwan believes proposal is ‘counterproductive’ and will not solve supply shortages
Swiss pharmaceutical company reports 55% jump in diagnostic sales
The pharmaceuticals are battling in similar markets, but their share price performances have diverged
‘If you look at the curves going up everywhere, relying on PCR alone will not work’
Supplier Roche warns of disruption as infections rise sharply
Patients in the US are waiting more than a week for results, by which time it’s probably too late
The question is how a return to work can be made safe without a vaccine?
Roche and Chugai provide lessons on how to keep a cross-border partnership intact
UK Edition
